GET DAILY SIGNALSSenseonics (SENS) Delivers Strong Q3 2026 Results with +140% Revenue Growth
Key Takeaways
- Senseonics reported third quarter 2026 net revenue of $19.6 million, up roughly 140% year over year and well above consensus estimates near $16.2 million.
- U.S. revenue climbed about 160% to $16.8 million, while revenue outside the U.S. rose roughly 65% to $2.8 million.
- Gross margin expanded to about 62% from 43% a year earlier, lifting gross profit to $12.1 million.
- Net loss widened to $32.7 million, or $0.50 per share, versus $19.5 million, or $0.43 per share, in the prior-year quarter.
- Management raised full-year 2026 revenue guidance to $68 million–$70 million and now expects gross margin above 60%.
- Cash, restricted cash, and short-term investments totaled $126.6 million as of September 30, 2026.
Earnings Context and Why It Matters
Senseonics is a diabetes technology company focused on redefining continuous glucose monitoring with its long-term, implantable Eversense sensor. This quarter provides a useful test of whether the Eversense 365 system—the only CGM with a full year on a single sensor—can turn rising patient adoption into lasting revenue growth. After bringing commercial operations in-house from its former partner Ascensia, Senseonics has delivered consecutive record quarters. I am watching closely to see if that momentum holds across the United States and in the newly launched European rollout, even as losses stay elevated.
Reported Results
For the third quarter ended September 30, 2026, Senseonics posted net revenue of $19.6 million, up approximately 140% from $8.1 million in the prior-year period and ahead of consensus estimates. U.S. revenue grew about 160% to $16.8 million, while revenue outside the U.S. rose about 65% to $2.8 million. Gross profit reached $12.1 million, with gross margin of about 62%, up from 43% a year earlier. This improvement reflects a favorable shift toward higher-priced bundled-pay sales and early Eversense 365 sales in Europe.
Net loss widened to $32.7 million, or $0.50 per share, from $19.5 million, or $0.43 per share, a year earlier, driven by higher research and development and selling, general, and administrative spending tied to commercialization. Management raised full-year 2026 revenue guidance to $68 million–$70 million, implying 93%–98% growth, and lifted its gross margin outlook to more than 60%. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Market Reaction and Investor Sentiment
Investor sentiment around Senseonics has strengthened through 2026 as the Eversense 365 rollout gained pace. Shares have climbed sharply over the trailing twelve months, and the post-earnings reaction reflected enthusiasm for the raised revenue forecast and the second consecutive quarterly revenue record. Analysts noted that revenue beat estimates by a wide margin, while the per-share loss was roughly in line with expectations. The key drivers of optimism are accelerating new patient starts—roughly nine out of ten new insertions involve patients switching from a competing sensor—and the expanding EON Care insertion network, which accounted for more than 40% of U.S. insertions in the quarter.
Forward Outlook and Key Factors to Monitor
Looking ahead, investors will be watching whether Senseonics can sustain its commercial momentum while managing an elevated cost base. The company’s new partnerships are a central catalyst: an integration with Sequel’s twiist insulin pump is already live, and a commercial launch with Beta Bionics’ iLet Bionic Pancreas is expected in the coming weeks. This could add an automated insulin delivery option that broadens the addressable patient pool.
On the product pipeline, Senseonics began first-in-human testing of its “Freedom” system in late October 2026. Freedom is designed to be the first CGM with no on-body component, and the company is targeting a pivotal study in 2027 and a potential launch in 2028. Progress on Freedom, along with the Gemini program, will be important longer-term drivers to monitor. Finally, investors should track margin trends, operating expenses, and cash utilization. Management expects full-year operating expenses slightly above its prior $150 million–$160 million range and has hinted that 2027 revenue could approach $100 million. Gross margin direction, reimbursement mix, and the pace of European adoption will help determine whether the current growth story translates into a narrower path toward profitability.
Using Tickeron’s AI Screener for Deeper Analysis
In my research process, I turned to Tickeron’s AI Screener to filter comparable names in the diabetes technology space and review technical patterns alongside fundamentals. The tool lets users scan thousands of stocks and ETFs with customizable filters on industry, market cap, volatility, and AI-driven signals, which helped surface additional context on how Senseonics stacks up against peers. It is a practical way to streamline screening without manual effort.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SENS in downward trend: price dove below 50-day moving average on November 02, 2026
SENS moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend. In 26 of 29 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 52 cases where SENS's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
The 10-day moving average for SENS crossed bearishly below the 50-day moving average on October 16, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SENS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
SENS broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for SENS entered a downward trend on November 03, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SENS's RSI Indicator exited the oversold zone, 40 of 46 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on SENS as a result. In 68 of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for SENS just turned positive on October 28, 2026. Looking at past instances where SENS's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
Following a +17.05% 3-day Advance, the price is estimated to grow further. Considering data from situations where SENS advanced for three days, in 198 of 243 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. SENS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 48 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.029) is normal, around the industry mean (4.142). P/E Ratio (-3.835) is within average values for comparable stocks, (3.291). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (9.058) is also within normal values, averaging (40.124).
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SENS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of transformative glucose monitoring products
Industry MedicalNursingServices
Advertisement